Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Enhertu
Pharma
AstraZeneca dual lung cancer wins softened by bispecific fail
The successes of Enhertu and Orpathys-Tagrisso in lung cancer niches were overshadowed by the phase 3 crash of volrustomig in first-line NSCLC.
Angus Liu
Aug 17, 2026 10:56am
Daiichi Sankyo flags accounting error; shares tank
Jul 31, 2026 11:39am
Merck-Kelun, China deal wisdom, Takeda—Fierce Pharma Asia
May 22, 2026 8:53am
Enhertu secures dual FDA approvals in early breast cancer
May 18, 2026 10:52am
Daiichi Sankyo targets global top 5 oncology rank by 2035
May 11, 2026 10:22am
Daiichi Sankyo takes $610M hit tied to ADC manufacturing losses
May 8, 2026 10:47am
